Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer
Can new drugs help advanced thyroid cancer patients keep their daily life stable?
An uncontrolled phase 2 trial of 22 patients with BRAF V600E-mutated thyroid cancer found encorafenib plus binimetinib was associated with g…
A new drug combination helped advanced thyroid cancer patients maintain daily life stability without worsening their quality of life during …
